Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novacet is a topical prescription medication containing a combination of sulfacetamide sodium (10%) and sulfur (5%). It is indicated for the treatment of dermatological conditions including acne vulgaris, rosacea, and seborrheic dermatitis. Sulfacetamide sodium is a sulfonamide antibiotic that exerts bacteriostatic activity by competitively inhibiting the enzyme dihydropteroate synthase, which is essential for bacterial folic acid synthesis. Sulfur acts as a keratolytic agent, promoting the shedding of dead skin cells and providing mild antiseptic and antifungal properties. Novacet is available in various topical forms, including lotions and cleansers, though it belongs to a class of older drugs that have not been formally evaluated by the FDA for safety and effectiveness under modern standards, often categorized under the Drug Efficacy Study Implementation (DESI) program.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Novacet.